Europe PMC
open access
Immunometabolism and rheumatic disease-advancing targeted therapies
Because so many pathways of intermediary metabolism are shared between immune cells and those essential for mammalian life, the possibility of targeting immunometabolism to treat rheumatic diseases long seemed fraught with risk. However, the discovery that targeting receptor-ligand interactions of g
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Chimeric antigen receptor T-cell therapy for rheumatic diseases: from B-cell depletion to immune reset and beyond.#630959
- Immune System Regulation: Inhibitory Checkpoint Receptors#169458
- Repurposing a detrimental antibody epitope as targeted therapeutics for sepsis and rheumatoid arthritis#1250736
- Synovial and Adipose Tissue Composition in Overweight/Obese Patients With Active Rheumatoid Arthritis Under JAK/STAT Inhibition#905323
- Inflammation in atherosclerosis: Drivers, mechanisms and therapies.#452859
Record · ID 1204006
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive